Latest news and press releases about Medicus Pharma Ltd. Common Stock (MDCX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Price
| Price | $0.16 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | -6.76 |
| EV / EBITDA | -0.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 17867.26% |
| Return on Invested Capital | -269.16% |
| Return on Assets | -204.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · BRNS · COEP · CUE · CVM · INMB · IPSC
Explore sector: Healthcare · Biotechnology
More sections of MDCX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks